Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lincomycin + lidocaine is a topical combination medication developed by Hubei Kangzheng Pharmaceutical, primarily indicated for the treatment of skin infections resulting from minor burns, trauma, and insect bites. Lincomycin is a lincosamide antibiotic that exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. Lidocaine is a local anesthetic of the amide type that provides symptomatic relief from pain and itching by blocking voltage-gated sodium channels, which prevents the initiation and conduction of nerve impulses. This formulation is commonly marketed in China as a gel (林可霉素利多卡因凝胶) and is approved for clinical use as an over-the-counter preparation for mild skin infections and inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lincomycin + lidocaine.